Dossier
ATTR-CM
Coverage of ATTR-CM in the Nexus archive.
- Push for Cath Lab Safety; Eplontersen Flops in ATTR-CM; Off-Label Testosterone Risks
A multisociety expert consensus statement advocates for enhanced radiation protection in cath labs. Eplontersen failed in trials for ATTR-CM, and off-label testosterone use is linked to risks.
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis Pharmaceuticals reported that their heart disease drug, Wainua, failed in a pivotal trial for ATTR-CM, showing no improvement over placebo in reducing cardiovascular death and clinical events. The failure caused AstraZeneca's U.S. shares to drop 8% and London-listed shares to fall 9%, while Ionis shares fell 12%.